Wall Street Zen Downgrades Aktis Oncology (NASDAQ:AKTS) to Sell

Aktis Oncology (NASDAQ:AKTS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

AKTS has been the topic of several other reports. HC Wainwright increased their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. William Blair started coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Raymond James Financial began coverage on Aktis Oncology in a report on Monday, June 15th. They set a “strong-buy” rating and a $40.00 target price on the stock. Finally, JPMorgan Chase & Co. boosted their price target on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.60.

Aktis Oncology Stock Performance

Aktis Oncology stock opened at $23.89 on Friday. The company has a 50 day simple moving average of $23.87. Aktis Oncology has a 1-year low of $14.72 and a 1-year high of $34.19. The stock has a market capitalization of $1.28 billion and a P/E ratio of -62.87.

Aktis Oncology (NASDAQ:AKTS) last issued its earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The business had revenue of $3.23 million for the quarter, compared to the consensus estimate of $2.23 million. Research analysts expect that Aktis Oncology will post -1.64 EPS for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.